✦ LIBER ✦

Older and new purine nucleoside analogs for patients with acute leukemias

✍ Scribed by Robak, Pawel; Robak, Tadeusz

Book ID: 120159769
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 438 KB
Volume: 39
Category: Article
ISSN: 0305-7372
DOI: 10.1016/j.ctrv.2013.03.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

New nucleoside analogs for patients with

New nucleoside analogs for patients with hematological malignancies

✍ Robak, Tadeusz 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 723 KB

Treatment of Older Patients With Acute M

Treatment of Older Patients With Acute Myeloid Leukemia—New Agents

✍ Alan K. Burnett; Unmesh Mohite 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 253 KB

Nonablative stem cell transplantation fo

Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes

✍ Sergio Giralt; Athanasios Anagnostopoulos; Munir Shahjahan; Richard Champlin 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Are low-intensity induction strategies b

Are low-intensity induction strategies better for older patients with acute myeloid leukemia?

✍ Gail J. Roboz; Usama Wissa; Ellen K. Ritchie; Usama Gergis; Sebastian Mayer; Jos 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 532 KB

The influence of farnesyl protein transf

The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro

✍ Anna Korycka; Piotr Smolewski; Tadeusz Robak 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 738 KB

Arsenic trioxide and low-dose cytarabine

Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia

✍ Gail J. Roboz; Ellen K. Ritchie; Tania Curcio; Juliette Provenzano; Rebecca Carl 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

## Abstract ## BACKGROUND. Acute myeloid leukemia (AML) carries a dismal prognosis in older patients. In this study, the authors evaluated the safety and efficacy of arsenic trioxide combined with low‐dose cytarabine in untreated patients aged ≥60 years with AML. ## METHODS. In a phase 1/2 desig